234 related articles for article (PubMed ID: 16820420)
21. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
22. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
[TBL] [Abstract][Full Text] [Related]
23. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
[TBL] [Abstract][Full Text] [Related]
24. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
25. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study.
Bentwich J; Dobronevsky E; Aichenbaum S; Shorer R; Peretz R; Khaigrekht M; Marton RG; Rabey JM
J Neural Transm (Vienna); 2011 Mar; 118(3):463-71. PubMed ID: 21246222
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
28. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
[TBL] [Abstract][Full Text] [Related]
29. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
[TBL] [Abstract][Full Text] [Related]
30. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
[TBL] [Abstract][Full Text] [Related]
31. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
32. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
Merrill CA; Jonsson MA; Minthon L; Ejnell H; C-son Silander H; Blennow K; Karlsson M; Nordlund A; Rolstad S; Warkentin S; Ben-Menachem E; Sjögren MJ
J Clin Psychiatry; 2006 Aug; 67(8):1171-8. PubMed ID: 16965193
[TBL] [Abstract][Full Text] [Related]
33. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
34. Influence of Educational Attainment on Cognition-Based Intervention Programs for Persons with Mild Alzheimer's Disease.
Contador I; Fernández-Calvo B; Ramos F; Olazarán J
J Int Neuropsychol Soc; 2016 May; 22(5):577-82. PubMed ID: 26976668
[TBL] [Abstract][Full Text] [Related]
35. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
37. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
38. Using Reiki to decrease memory and behavior problems in mild cognitive impairment and mild Alzheimer's disease.
Crawford SE; Leaver VW; Mahoney SD
J Altern Complement Med; 2006 Nov; 12(9):911-3. PubMed ID: 17109583
[TBL] [Abstract][Full Text] [Related]
39. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
[TBL] [Abstract][Full Text] [Related]
40. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Olazarán J; Muñiz R; Reisberg B; Peña-Casanova J; del Ser T; Cruz-Jentoft AJ; Serrano P; Navarro E; García de la Rocha ML; Frank A; Galiano M; Fernández-Bullido Y; Serra JA; González-Salvador MT; Sevilla C
Neurology; 2004 Dec; 63(12):2348-53. PubMed ID: 15623698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
